Efficacy of using synbiotics during neoadjuvant chemotherapy in esophageal cancer patients

Efficacy of using synbiotics during neoadjuvant chemotherapy in esophageal cancer patients - Synbiotics during neoadjuvant chemotherapy in esophageal cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006875

Enrollment

Registered

2011-12-14

Start date

2011-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

esophageal cancer

Interventions

Yakult BL Seichoyaku (Yakult Honsha, Japan) galactoorigosaccharides (Oligomate S-HP, Yakult Honsha, Japan) Biofermin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with histologically confirmed primary esophageal cancer, who are scheduled to receive neoadjuvant chemotherapy -Performance status is 0-2 -No serious abnormality in heart, lung, bone marrow, liver, and renal functions

Exclusion criteria

Exclusion criteria: Patients who have narrowing of esophago-intestinal lumen Patients who are judged inappropriate for the entry into the study by the investigater

Design outcomes

Primary

Measure	Time frame
Incidence of adverse events during chemotherapy	—

Secondary

Measure	Time frame
Nutritional parameter, fecal microflora, fecal organic acid	—

Countries

Japan

Contacts

Public ContactMasaaki Motoori

Osaka Medical Center for Cancer and Cardiovascular Diseases Surgery

motoori-ma@mc.pref.osaka.jp06-6972-1181

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026